Financial reports
10-K/A
2023 FY
Annual report (amended)
16 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
19 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
25 Mar 24
8-K
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
21 Mar 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis
21 Nov 23
8-K
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
9 Nov 23
8-K
Departure of Directors or Certain Officers
21 Sep 23
8-K
Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid Models
14 Sep 23
8-K
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
9 Aug 23
8-K
Departure of Directors or Certain Officers
30 May 23
8-K
Landos Biopharma Announces 1-for-10 Reverse Stock Split
25 May 23
Registration and prospectus
S-8
Registration of securities for employees
21 Mar 24
S-8
Registration of securities for employees
23 Mar 23
S-3/A
Shelf registration (amended)
11 Aug 22
S-3
Shelf registration
24 Mar 22
S-8
Registration of securities for employees
24 Mar 22
S-8
Registration of securities for employees
17 May 21
424B4
Prospectus supplement with pricing info
4 Feb 21
S-1/A
IPO registration (amended)
1 Feb 21
8-A12B
Registration of securities on exchange
1 Feb 21
S-1/A
IPO registration (amended)
28 Jan 21
Proxies
DEFM14A
Proxy related to merger
25 Apr 24
PREM14A
Preliminary proxy related to merger
15 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Mar 24
DEFA14A
Additional proxy soliciting materials
25 Mar 24
DEFA14A
Additional proxy soliciting materials
25 Mar 24
DEF 14A
Definitive proxy
19 Apr 23
PRE 14A
Preliminary proxy
10 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
Other
EFFECT
Notice of effectiveness
16 Aug 22
CORRESP
Correspondence with SEC
11 Aug 22
CORRESP
Correspondence with SEC
18 May 22
CORRESP
Correspondence with SEC
16 May 22
UPLOAD
Letter from SEC
30 Mar 22
EFFECT
Notice of effectiveness
4 Feb 21
CERT
Certification of approval for exchange listing
2 Feb 21
CORRESP
Correspondence with SEC
1 Feb 21
CORRESP
Correspondence with SEC
1 Feb 21
CORRESP
Correspondence with SEC
1 Feb 21
Ownership
SC 13D/A
PERCEPTIVE ADVISORS LLC
10 Apr 24
SC 13D/A
Xontogeny, LLC
10 Apr 24
4
Fabio Cataldi
4 Mar 24
4
Gregory Oakes
4 Mar 24
SC 13G/A
Bassaganya-Riera Josep
14 Feb 24
4
Alka Batycky
1 Jun 23
3
Alka Batycky
1 Jun 23
4
TIMOTHY M MAYLEBEN
24 May 23
4
Tiago Girao
24 May 23
4
Christopher Nishan Garabedian
24 May 23